Pathologic features of vascular endothelial growth factor-induced retinopathy in the nonhuman primate.

PURPOSE Vascular endothelial growth factor (VEGF) is a potent ischemia-upregulated angiogenic protein that has been implicated in diabetic retinopathy. Intravitreal VEGF injections have not previously been shown to produce preretinal neovascularization. The purpose of this study was to further characterize the angiopathic changes that occur after intravitreal injections in a nonhuman primate and determine if preretinal neovascularization develops. DESIGN Experimental animal study. METHODS Vascular endothelial growth factor 165 was injected into the eyes of normal cynomolgus monkeys at regular intervals. As a control, normal eyes were injected with phosphate buffered saline. Color photography and fluorescein angiography were performed at regular intervals. The retinas were incubated for adenosine diphosphatase (ADPase) activity to visualize retinal vessels. The retinas were flat-embedded and areas of potential preretinal neovascularization were identified en bloc and serially sectioned. RESULTS Areas of capillary nonperfusion and vessel dilation and tortuousity were seen by angiography. In serial sections, the nonperfused areas were found to be associated with endothelial cell hyperplasia in vessel lumens. Preretinal neovascularization originating only from superficial veins and venules was observed throughout peripheral retina, but was not seen in the posterior pole. Lacunae-like veins were subdivided by the process of intussusception and endothelial cell bridging. Arterioles demonstrated endothelial cell hyperplasia and microaneurysms. CONCLUSION Intraocular injections of VEGF were sufficient to produce preretinal neovascularization in the nonhuman primate. Most vasculopathic structures were associated with endothelial cell hyperplasia. These results demonstrate that VEGF alone can produce many features of both nonproliferative and proliferative diabetic retinopathy including the previously undescribed development of preretinal neovascularization. This well-characterized VEGF-induced primate model of retinal neovascularization may be useful as a means of testing new treatments for retinal neovascularization.

[1]  G. Lutty,et al.  Vascular endothelial growth factor and vascular permeability changes in human diabetic retinopathy. , 1997, Investigative ophthalmology & visual science.

[2]  D McLeod,et al.  Three dimensional analysis of microaneurysms in the human diabetic retina , 1999, Journal of anatomy.

[3]  Joan W. Miller,et al.  Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model. , 1994, The American journal of pathology.

[4]  H. Suzuki,et al.  Ocular vascular endothelial growth factor levels in diabetic rats are elevated before observable retinal proliferative changes , 1997, Diabetologia.

[5]  Joan W. Miller,et al.  Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. , 1994, American journal of ophthalmology.

[6]  G. Schmid-Schönbein,et al.  Activated monocytes and granulocytes, capillary nonperfusion, and neovascularization in diabetic retinopathy. , 1991, The American journal of pathology.

[7]  J. Tarbell,et al.  Vascular permeability in experimental diabetes is associated with reduced endothelial occludin content: vascular endothelial growth factor decreases occludin in retinal endothelial cells. Penn State Retina Research Group. , 1998, Diabetes.

[8]  J. Isner,et al.  Arterial gene transfer of naked DNA for therapeutic angiogenesis: early clinical results. , 1998, Advanced drug delivery reviews.

[9]  D. Foreman,et al.  VEGF localisation in diabetic retinopathy , 1998, The British journal of ophthalmology.

[10]  E S Gragoudas,et al.  Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate. , 1996, Archives of ophthalmology.

[11]  Y. Hata,et al.  Vascular endothelial growth factor plays a role in hyperpermeability of diabetic retinal vessels. , 1995, Ophthalmic research.

[12]  M. Runge,et al.  Therapeutic myocardial angiogenesis via vascular endothelial growth factor gene therapy: moving on down the road. , 2000, Circulation.

[13]  E S Gragoudas,et al.  Intravitreous injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate. , 1996, Ophthalmology.

[14]  K. Miyarnoto.  Prevention of leukostasis and vascular leakage in streptozotocin-induced diabetic retinopathy via intercellular adhesion molecule-1 inhibition , 1999 .

[15]  J. Isner,et al.  Left Ventricular Electromechanical Mapping to Assess Efficacy of phVEGF165 Gene Transfer for Therapeutic Angiogenesis in Chronic Myocardial Ischemia , 2000, Circulation.

[16]  P A D'Amore,et al.  Inhibition of capillary endothelial cell growth by pericytes and smooth muscle cells , 1987, The Journal of cell biology.

[17]  G. Lutty,et al.  Localization of vascular endothelial growth factor in human retina and choroid. , 1996, Archives of ophthalmology.

[18]  L. Aiello,et al.  Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[19]  L. Aiello,et al.  Prevention of leukostasis and vascular leakage in streptozotocin-induced diabetic retinopathy via intercellular adhesion molecule-1 inhibition. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[20]  K Miyamoto,et al.  In vivo demonstration of increased leukocyte entrapment in retinal microcirculation of diabetic rats. , 1998, Investigative ophthalmology & visual science.

[21]  C. Zucker,et al.  Expression of vascular endothelial growth factor in the human retina and in nonproliferative diabetic retinopathy. , 1998, The American journal of pathology.

[22]  K. Kawasaki,et al.  Upregulation of Retinal Vascular Endothelial Growth Factor mRNAs in Spontaneously Diabetic Rats without Ophthalmoscopic Retinopathy , 1998, Ophthalmic Research.

[23]  Alan W. Stitt,et al.  Histological and ultrastructural investigation of retinal microaneurysm development in diabetic patients. , 1995, The British journal of ophthalmology.

[24]  Joan W. Miller,et al.  Vascular endothelial growth factor is sufficient to produce iris neovascularization and neovascular glaucoma in a nonhuman primate. , 1996, Archives of ophthalmology.

[25]  D. S. Mcleod,et al.  A new technique for visualization of the human retinal vasculature. , 1992, Archives of ophthalmology.

[26]  Dian Feng,et al.  Heterogeneity of the Angiogenic Response Induced in Different Normal Adult Tissues by Vascular Permeability Factor/Vascular Endothelial Growth Factor , 2000, Laboratory Investigation.

[27]  P. Campochiaro,et al.  Intravitreal Sustained Release of VEGF Causes Retinal Neovascularization in Rabbits and Breakdown of the Blood– Retinal Barrier in Rabbits and Primates , 1997 .

[28]  K Miyamoto,et al.  VEGF increases retinal vascular ICAM-1 expression in vivo. , 1999, Investigative ophthalmology & visual science.

[29]  A. Garner.  Histopathology of diabetic retinopathy in man , 1993, Eye.

[30]  A Mathis,et al.  Detection of vascular endothelial growth factor messenger RNA and vascular endothelial growth factor-like activity in proliferative diabetic retinopathy. , 1994, Archives of ophthalmology.

[31]  L. Aiello,et al.  Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. , 1994, The New England journal of medicine.

[32]  R O Bonow,et al.  Clinical trials in coronary angiogenesis: issues, problems, consensus: An expert panel summary. , 2000, Circulation.